VRNA vs. PVLA

Last updated Jun 24, 2026

VRNA (Verona Pharma plc) and PVLA (Palvella Therapeutics, Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. At a 0.06 correlation, their price movements are largely independent.

Performance

VRNA vs. PVLA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Verona Pharma plc (VRNA) and Palvella Therapeutics, Inc (PVLA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

PVLA

• 1D: -0.13%
• 1M: 4.11%
• YTD: 13.38%
• 6M: 18.36%
• 1Y: 426.53%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

VRNA vs. PVLA - Yearly Performance Comparison

	2026 (YTD)	2025	2024
VRNA Verona Pharma plc	0.00%	130.21%	12.12%
PVLA Palvella Therapeutics, Inc	13.38%	772.25%	-8.27%

Correlation

The correlation between VRNA and PVLA is 0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.03
Correlation (All Time) Calculated using the full available price history since Dec 16, 2024	0.06

Fundamentals

Market Cap VRNA : $9.72B PVLA : $1.34B
EPS VRNA : -$0.69 PVLA : -$3.75
PB Ratio VRNA : 34.92 PVLA : 47.72
Total Revenue (TTM) VRNA : $167.65M PVLA : $0.00
Gross Profit (TTM) VRNA : $159.52M PVLA : $0.00
EBITDA (TTM) VRNA : -$40.86M PVLA : -$14.75M

Return for Risk

VRNA vs. PVLA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VRNA

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

PVLA

PVLA Risk / Return Rank: 97
PVLA Sharpe Ratio Rank: 99
PVLA Sortino Ratio Rank: 97
PVLA Omega Ratio Rank: 95
PVLA Calmar Ratio Rank: 99
PVLA Martin Ratio Rank: 98

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VRNA vs. PVLA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and Palvella Therapeutics, Inc (PVLA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	VRNA	PVLA	Difference
Sharpe ratio: Return per unit of total volatility	—	5.32	—
Sortino ratio: Return per unit of downside risk	—	4.47	—
Omega ratio: Gain probability vs. loss probability	—	1.54	—
Calmar ratio: Return relative to maximum drawdown	—	13.82	—
Martin ratio: Return relative to average drawdown	—	31.14	—

Drawdowns

Drawdown Indicators

	VRNA	PVLA	Difference
Max Drawdown Largest peak-to-trough decline	—	-31.48%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-31.11%	—
Current Drawdown Current decline from peak	—	-19.99%	—
Average Drawdown Average peak-to-trough decline	—	-11.16%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	13.79%	—

Volatility

Volatility by Period

	VRNA	PVLA	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	19.68%	—
Volatility (6M) Calculated over the trailing 6-month period	—	61.91%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	80.85%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	82.11%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	82.11%	—

Dividends

VRNA vs. PVLA - Dividend Comparison

Neither VRNA nor PVLA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both VRNA and PVLA in my portfolio?

VRNA and PVLA have a correlation of 0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.